TABLE 2

Subgroup analysis of inhaled corticosteroid (ICS) versus non-ICS treatment, stratified by blood eosinophil group and by baseline exacerbation frequency

Low-eosinophil group
(<150 cells·µL−1)
High-eosinophil group
(≥150 cells·µL−1)
Interaction HR and p-value
Low exacerbation rate (0 or 1)1.21 (1.10–1.34)
p=0.001
n=2299
1.07 (1.00–1.15)
p=0.06
n=5068
0.88 (0.78–0.99)
p=0.04
Higher exacerbation rate (≥2)1.18 (0.97–1.44)
p=0.11
n=498
0.94 (0.82–1.07)
p=0.34
n=1102
0.79 (0.62–1.00)
p=0.06

Data are presented as hazard ratio (HR) (95% CI), unless otherwise stated. HRs are for time to first exacerbation after treatment initiation, for ICS versus non-ICS treatment. HRs are from Cox regression including the interaction term and adjusted for covariates, as listed in figure 1. n=9007.